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osteoarthritis and rheumatoid arthritis. From a third party per-
spective, this model allows customization with respect to clini-
cal and cost inputs, as well as treatment patterns.
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OBJECTIVES: One of the main treatment goals in rheumatoid
arthritis (RA), for which there is no curative treatment so far, is
to improve Health Related Quality of Life (HRQoL) and patient
satisfaction with treatment. The Willingness to pay (WTP)
method can be used as a tool to assess patient preferences and
the perceived value of non-marketed goods intangible goods.
Although the efﬁcacy of adalimumab and inﬂiximab in the treat-
ment of RA might be the same, the differences in administration
route and dosage might impact patient preferences and perceived
value of the drugs. METHODS: We carried out a WTP study in
RA patients, currently treated with inﬂiximab, assessing patient’s
WTP in the open-ended with follow-up format. We presented a
new treatment, adalimumab, with the same efﬁcacy as inﬂiximab
but with some differential attributes, mainly the possibility to
self-administer the subcutaneous injection, administration at
home, minor time for administration, ergonomic design for being
self-administrating, and ﬁnally presentation just for being used.
RESULTS: In total, 91 patients were included in the study, of
which 76 (83.5%) were WTP for the new treatment. The mean
WTP was 103.4€ per month, which represents the 9% of the
patient’s monthly rent. Patients with poorest health states pre-
sented the lowest monthly WTP as compared with those with
the best-perceived health state (83€ vs. 121€). No differences
were found in the WTP according to other sociodemographic or
clinical variables. CONCLUSIONS: The new treatment is pre-
ferred by most of AR patients, mainly due to the reduced admin-
istration time, which drives a willingness to pay of 9% of the
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OBJECTIVE: To evaluate from the payer’s perspective the cost-
effectiveness of adding the NK1 receptor antagonist aprepitant
to ondansetron/dexamethasone in patients undergoing highly
emetogenic chemotherapy in ofﬁce-based settings in Germany.
METHODS: We compared aprepitant in combination with
ondansetron/dexamethasone to ondansetron/dexamethasone
alone over a single chemotherapy cycle. To that end a decision-
analytic model based on clinical results and resource utilization
observed in aprepitant Phase III trials was constructed. Health
outcomes included complete response (no emesis, no rescue
therapy) and quality-adjusted life years (QALYs). Utility values
were obtained from the literature. German tariffs and prices were
used to cost health care resources. A series of sensitivity analy-
ses was conducted. RESULTS: In the aprepitant group (N = 514)
68% of the patients were complete responders over the entire
chemotherapy cycle compared to 48% in the standard care
group (N = 518). More patients were emesis-free over the entire
chemotherapy cycle with aprepitant regimen (72%) compared to
standard regimen (49%). Cost difference between aprepitant
regimen and standard therapy was 37€, with 43% of the aprepi-
tant drug cost being offset by lower resource use in the aprepi-
tant group. Incremental cost per QALY gained with aprepitant
was 21,764€. Results were most sensitive to costs of hospital-
izations and rescue medications. CONCLUSIONS: Signiﬁcantly
more patients were estimated being emesis-free when adding
aprepitant to antiemetic standard therapy, with a signiﬁcant pro-
portion of the cost of aprepitant being offset. Use of aprepitant
in ofﬁce-based settings in Germany proved to be cost-effective.
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OBJECTIVES: To assess the incremental cost-effectiveness of
imatinib relative to interferon alfa plus low-dose cytarabine
(IFN+LDAC) as 1st-line therapy for patients newly diagnosed
with chronic phase CML. METHODS: An economic simulation
model was developed using Microsoft Excel to estimate lifetime
costs, survival and quality-adjusted survival. Data collected in
the International Randomized Interferon vs. STI571 Study (IRIS)
and supplemental data from the literature were used to populate
the model. Patients initially treated with imatinib could switch
to IFN+LDAC and vice-versa for patients started on IFN+LDAC,
with both arms eventually switching to hydroxyurea as 3rd-line
treatment. Long-term survival was modeled on complete cyto-
genetic response (CCyR) after 2 years. Published survival curves
for patients with or without complete CCyR after treatment with
interferon alfa were used to estimate long-term survival.
RESULTS: The results of our cost-effectiveness model showed
that patients treated 1st-line with imatinib were projected to live
for approximately 15.13 years while those treated 1st-line with
IFN+LDAC were projected to live for approximately 10.75
years. Undiscounted lifetime costs were estimated at approxi-
mately $456,000 for patients receiving imatinib and $286,194
for patients receiving IFN+LDAC. After applying a 5% discount
rate, the incremental gain in survival was estimated at 2.09 life-
year and 1.91 quality adjusted life-year in favour of imatinib.
Due to the increased survival, the incremental discounted life-
time costs were approximately $96,118 higher among patients
treated with imatinib, resulting in cost-effectiveness ratios of
Can$45,537/LY saved and Can$49,953/QALY. Assumptions
that affected duration or costs of the treatments had the largest
impact on the ICERs. CONCLUSIONS: Our analysis showed
that imatinib offers both longevity and quality of life beneﬁts.
Furthermore, compared to IFN+LDAC, imatinib proved to be a
cost-effective 1st-line therapy for patients with newly diagnosed
chronic phase CML.
